Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.

The company dribbles out more data on IMA203, and the numbers head in the right direction.

Keyvibe-010 fails, but not for the reason you might have expected.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.